Questions are swirling about the upcoming Inflation Reduction Act (IRA) drug changes — and for good reason. In just a few months, covered entities will have to navigate the challenges of handling the first 10 drugs reimbursed at the Maximum Fair Price (MFP). Both entities and pharmacies will be required to adapt quickly to this new reality — with significant implications for 340B savings, compliance, and access.
This is a critical topic with major financial and operational implications — and many details are still evolving. Staying informed and proactive is essential to avoid disruption and maximize your program outcomes.
